Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) went up by 12.64% from its latest closing price compared to the recent 1-year high of $7.45. The company’s stock price has collected 45.56% of gains in the last five trading sessions. Press Release reported on 02/05/21 that Thinking about buying stock in Zomedica, Nokia, Zynerba Pharmaceuticals, Senseonics Holdings, or Atossa Therapeutics?
Is It Worth Investing in Zynerba Pharmaceuticals Inc. (NASDAQ :ZYNE) Right Now?
Plus, the 36-month beta value for ZYNE is at 2.84. Opinions of the stock are interesting as 5 analysts out of 7 who provided ratings for Zynerba Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 2 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $7.42, which is $2.34 above the current price. ZYNE currently public float of 27.11M and currently shorts hold a 15.35% ratio of that float. Today, the average trading volume of ZYNE was 2.76M shares.
ZYNE’s Market Performance
ZYNE stocks went up by 45.56% for the week, with a monthly jump of 48.97% and a quarterly performance of 44.73%, while its annual performance rate touched -0.97%. The volatility ratio for the week stands at 15.80% while the volatility levels for the past 30 days are set at 7.28% for Zynerba Pharmaceuticals Inc.. The simple moving average for the period of the last 20 days is 39.27% for ZYNE stocks with a simple moving average of 26.03% for the last 200 days.
Analysts’ Opinion of ZYNE
Many brokerage firms have already submitted their reports for ZYNE stocks, with H.C. Wainwright repeating the rating for ZYNE by listing it as a “Buy.” The predicted price for ZYNE in the upcoming period, according to H.C. Wainwright is $9 based on the research report published on December 21st of the previous year 2020.
ROTH Capital gave a rating of “Buy” to ZYNE, setting the target price at $12 in the report published on December 31st of the previous year.
ZYNE Trading at 32.94% from the 50-Day Moving Average
After a stumble in the market that brought ZYNE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -31.81% of loss for the given period.
Volatility was left at 7.28%, however, over the last 30 days, the volatility rate increased by 15.80%, as shares surge +45.56% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +22.12% upper at present.
During the last 5 trading sessions, ZYNE rose by +45.56%, which changed the moving average for the period of 200-days by +27.00% in comparison to the 20-day moving average, which settled at $3.73. In addition, Zynerba Pharmaceuticals Inc. saw 53.94% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for ZYNE
The total capital return value is set at -51.40, while invested capital returns managed to touch -49.42. Equity return is now at value -74.20, with -63.80 for asset returns.
Based on Zynerba Pharmaceuticals Inc. (ZYNE), the company’s capital structure generated 0.47 points at debt to equity in total, while total debt to capital is 0.47. Total debt to assets is 0.40, with long-term debt to equity ratio resting at 0.15. Finally, the long-term debt to capital ratio is 0.14.
The liquidity ratio also appears to be rather interesting for investors as it stands at 7.20.